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Congenital disorders of glycosylation (CDGs) are disorders of abnormal protein glycosylation that affectmultiple organ systems. Because
most CDGs have been described in only a few individuals, our understanding of the associated phenotypes and the mechanisms of in-
dividual survival are limited. In the process of studying two siblings, aged 6 and 11 years, with MOGS-CDG and biallelic MOGS (man-
nosyl-oligosaccharide glucosidase) mutations (GenBank: NM_006302.2; c.[65C>A; 329G>A] p.[Ala22Glu; Arg110His]; c.[370C>T]
p.[Gln124*]), we noted that their survival was much longer than the previous report of MOGS-CDG, in a child who died at 74 days
of age. Upon mutation analysis, we detected multiple MOGS genotypes including wild-type alleles in their cultured fibroblast and pe-
ripheral blood DNA. Further analysis of DNA from cultured fibroblasts of six individuals with compound heterozygous mutations of
PMM2 (PMM2-CDG), MPI (MPI-CDG), ALG3 (ALG3-CDG), ALG12 (ALG12-CDG), DPAGT1 (DPAGT1-CDG), and ALG1 (ALG1-CDG)
also identified multiple genotypes including wild-type alleles for each. Droplet digital PCR showed a ratio of nearly 1:1 wild-type to
mutant alleles for most, but not all, mutations. This suggests that mitotic recombination contributes to the survival and the variable
expressivity of individuals with compound heterozygous CDGs. This also provides an explanation for prior observations of a reduced
frequency of homozygous mutations and might contribute to increased levels of residual enzyme activity in cultured fibroblasts of in-
dividuals with MPI- and PMM2-CDGs.Protein glycosylation takes place in the cytoplasm, endo-
plasmic reticulum, and Golgi apparatus. Throughout this
process, branching linkages of various monosaccharides
are added to the amide group of asparagine (N-linked) or
the hydroxyl group of serine or threonine (O-linked) (see
GeneReviews inWeb Resources). Since the first description
of ‘‘Congenital Disorders of Glycosylation (CDGs)’’ in
1980, more than 100 different CDGs have been described
affecting protein and lipid glycosylation.1–4 Nearly 60
different disorders in N-linked glycosylation have been re-
ported to date.4 CDGs are defined as either type I defects,
involving improper assembly or transfer of dolichol-linked
glycans to proteins in the ER, or type II defects, resulting
from incorrect modification of the protein-attached gly-
cans in the Golgi.5
The CDGs cause multi-system disease, have a wide range
of clinical presentations, and manifest variable expressiv-
ity.6 The pleiotropism of the CDGs can be partially attrib-
uted to the fact that ~50% of human proteins are glycosy-
lated and that some glycosylation events are tissue
specific.7 A peculiar observation of the CDGs is that very
few individuals have homozygous mutations compared
to compound heterozygous mutations.8–13 Combined
with biochemical assays for residual enzyme activity and
studies of animal models, this paucity of homozygous mu-
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The Americconveying residual catalytic activity is required for sur-
vival.10,12,14–16 It has been proposed that homozygous mu-
tations are either lethal (due to null alleles) or result in a
subclinical phenotype (due to hypomorphic alleles), attrib-
uted to a wide tolerance of enzymatic activity as reported
in unaffected individuals.9,16 Indeed, Helander et al. have
reported two siblings with subclinical presentation of
homozygous MPI-CDG due to a variant also found in com-
pound heterozygous MPI-CDG-affected individuals.17
Another unexplained observation among the CDGs is
that cultured skin fibroblasts derived from individuals
with PMM2-CDG (OMIM: 212065) have high residual
enzymatic activity.9
To better understand factors contributing to the pro-
longed survival of individuals with CDGs, we studied
two siblings diagnosed with MOGS-CDG (OMIM:
606056). In contrast to the previously reported individual
who died at 74 days of age,18 these individuals have sur-
vived into late childhood. A 6-year-old female (individual
A) and her 11-year-old brother (individual B), both of
European descent, were admitted to the National Institutes
of Health Clinical Center under the NHGRI IRB-approved
protocol 76-HG-0238, ‘‘Diagnosis and Treatment of
Patients with Inborn Errors of Metabolism or Other
Genetic Disorders.’’ Written, informed consent was also
obtained for both individuals. Both children demonstratedIH, Bethesda, MD 20892, USA; 2National Human Genome Research Insti-
tional Medical Center, Washington, DC 20010, USA; 4Human Genetics Pro-
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Figure 1. MOGS SNV Analysis in Individuals A and B
(A) Sanger sequencing of MOGS in the parents and individuals A and B reveal two paternally inherited variants at c.65C>A and
c.329G>A and one maternally inherited variant at c.370C>T.
(B) Analysis of SNV reference allele frequency by digital PCR in the fibroblasts from MOGS-CDG individual A (Ind A) shows no signif-
icant loss of alleles at the three inherited SNVs in vitro.
(C) Digital PCR analysis of SNValleles in blood-derived DNA shows no loss of alleles in eitherMOGS-CDG-affected individual (Ind A and
Ind B) nor their parents (Mother and Father) in vivo.
Error bars indicate SD.dysmorphic facial features, severe intellectual disability,
optic atrophy, mild generalized cerebral atrophy and cere-
bellar atrophy with thin corpus callosum, hypotonia,
persistent leukocystosis, and hypogammaglobinemia. A
description of the abnormal immunological phenotype
of these individuals has been previously published.19
Sanger DNA sequencing of PCR-amplified mannosyl-
oligosaccharide glucosidase (MOGS [OMIM: 601336]) cod-
ing exons identified mutations (GenBank: NM_006302.2;
c.[65C>A; 329G>A];[370C>T]) (Figure 1A). The accession
numbers for these SNVs are dbSNP: rs753961807
(c.65C>A) and rs587777323 (c.370C>T) and ClinVar:
SCV000256097 (c.329G>A).
The paternal mutations encode p.Ala22Glu and
p.Arg110His, alterations of two conserved amino acids.340 The American Journal of Human Genetics 98, 339–346, FebruaryThematernal mutation encodes p.Gln124*. The paternally
inherited single-nucleotide variants (SNVs) are predicted
by in silico analysis to alter mRNA splicing and protein
stability, respectively. The maternally inherited SNV is ex-
pected to trigger nonsense-mediated decay of the mRNA.
At this time, unlike for PMM2 and MPI activity, there is
no establishedmethod for measuringMOGS enzymatic ac-
tivity, making it difficult to examine the enzymatic func-
tion of these mutations.
In light of these in silico predictions, we sought to
better characterize the MOGS mRNA expressed in fibro-
blasts from individuals A and B. We amplified, cloned,
and sequenced individual cDNA clones. This identified
allelic combinations of SNVs absent in the parents
(data not shown). To delineate the frequency and origin4, 2016
Table 1. Single-Allele Sequencing Results of MOGS-CDG-Affected Individuals
Sample
MOGS
c.65C>A
MOGS
c.329G>A
MOGS
c.370C>T
Ind. A,
Fibroblast
(n ¼ 130)
Ind. B,
Fibroblast
(n ¼ 126)
Ind. A,
Blooda
(n ¼ 100)
Ind. B,
Blooda
(n ¼ 108)
Ind. A,
Bloodb
(n ¼ 3,896)
Ind.B,
Bloodb
(n ¼ 5,305)
Genotype and
Frequency
A A T 7.69% 3.97% 4% 6.48% 3.26% 3.05%
C* G* C* 6.92% 13.49% 0 6.48% 3.82% 2.53%
A G* C* 19.23% 13.49% 0 0 2.62% 2.21%
C* A C* 10.00% 7.14% 2% 2.78% 3.80% 3.02%
C* A T 3.85% 6.35% 0 0.93% 1.13% 0.60%
A G* T 11.54% 14.29% 0 2.78% 3.52% 1.79%
A A C* 27.69% 15.87% 45% 50.93% 69.99% 83.03%
C* G* T 7.69% 25.40% 49% 29.63% 11.86% 3.77%
Total non-parental clonesa/readsb 59.23% 58.73% 6% 19.44% 18.15% 13.20%
Single-allele cloning and sequencing and PacBio amplicon sequencing reveal non-parental genotypes in the fibroblast- and blood-derived DNA from individuals
(Ind.) A and B. The total number (n) of alleles sequenced is indicated for each sample type. The allele genotype at each of the three variant sites is shown in the first
three columns; reference alleles are indicated with an asterisk. Each row represents a single allele and the allelic percentage among the sequenced population from
fibroblast or blood genomic DNA is shown in the adjacent columns as indicated. The last two rows of allele genotypes represent the inherited, parental genotypes.
aSingle-allele cloning and sequencing.
bPacBio amplicon sequencing.of these non-parental genotypes, we amplified and
sequenced >100 clones of the region of genomic DNA
encompassing the inherited SNVs (Table 1). Approxi-
mately 60% of the clones for both individuals had re-
combinant, non-parental genotypes (Table 1); 7% and
13% had a wild-type genotype for individuals A and B,
respectively. To determine whether non-parental geno-
types also occurred in vivo, we analyzed R100 clones
and >3,500 PacBio amplicons derived from the blood
DNA of both MOGS-CDG-affected individuals. We found
6% and 18% non-parental genotypes for individual A
and 19% and 13% non-parental genotypes for individual
B (Table 1).
The observed genotypes suggest a rearrangement of ge-
netic information during mitosis, which can be triggered
by DNA double-strand breaks (DSBs) and subsequent
homology-directed repair.20 Mitotic recombination of
chromosomes has been well characterized in model or-
ganisms and can result in either reciprocal or non-recip-
rocal transfer of genetic information between chromo-
somes.21 In the case of reciprocal recombination, a
chromosomal crossover event is resolved with no loss
of genetic information; this is the mechanism underlying
meiotic recombination. Non-reciprocal recombination re-
sults in the loss of genetic information, usually from the
damaged allele during DSB repair. The result is a loss of
heterozygosity at the repair locus such that both alleles
carry the donor or template genotype, e.g., gene conver-
sion.20 Reciprocal recombination inherently requires
crossing-over and the number of crossing-over events be-
tween chromatids will determine the amount of genetic
material that is exchanged. A single cross-over event
will result in a complete allelic switch between chroma-
tids from the site of cross-over through the distal armThe Americof the chromosome. Double cross-over events will limit
the region of recombination to a shorter segment of
the chromosome.22
To test whether reciprocal or nonreciprocal mitotic
recombination processes are responsible for the non-
parental genotypes observed in cultured fibroblasts and
blood from the MOGS-CDG-affected individuals, we
used the RainDrop digital PCR system and custom
TaqMan genotyping assays to test the frequency of the in-
herited SNVs (sequences in Table S1). By employing digi-
tal PCR, we were able to determine the genotype at the
SNV of interest on thousands of individual alleles from
fibroblast or blood DNA. This allowed for more accurate
quantification of the reference and variant allele fre-
quency versus the relative signal quantification that could
be achieved using real-time PCR with these same genotyp-
ing assays. Analysis of the fibroblasts derived from indi-
vidual A showed no significant loss of alleles in vitro
(p > .9 by chi-square analysis). Likewise, analyses of
blood-derived DNA showed no skewing in the frequency
of the three SNVs for either MOGS-CDG-affected individ-
ual (Figure 1C), supporting a reciprocal mitotic intragenic
recombination process as the origin of the non-parental
genotypes in vivo.
Based on these observations, we proposed that mitotic
intragenic recombination accounts for the reported
paucity of homozygous versus compound heterozygous
mutations associated with CDGs and is a mechanism for
individual survival. Blood-derived DNA was unavailable,
so we tested this using genomic DNA isolated from
cultured fibroblast lines derived from individuals with
compound heterozygous mutations of PMM2 (PMM2-
CDG [OMIM: 212065]), MPI (MPI-CDG [OMIM:
602579]), ALG3 (ALG3-CDG [OMIM: 601110]), ALG12an Journal of Human Genetics 98, 339–346, February 4, 2016 341
Table 2. Single-Allele Sequencing Results of Additional CDGs
Disease (Mutations), Accession Genotype Category Percentage
c.395 c.430 (n ¼ 105)
PMM2-CDG (PMM2: c.[395T>C]; [430T>C]), dbSNP: rs150719105, rs80338702 C C mut 2.86
T* T* WT 1.9
C T* het 46.67
T* C het 48.57
Total non-parental 4.76
c.1205 c.1253 (n ¼ 121)
MPI-CDG (MPI: c.[1205A>G];[1253G>A]), ClinVar: SCV000256094, SCV000256095 G A mut 0
A* G* WT 1.65
A* A het 48.76
G G* het 49.59
Total non-parental 1.65
c.211 c.470 (n ¼ 135)
ALG3-CDG (ALG3: c.[211T>C];[470T>A]), dbSNP: rs119103237, rs119103238 C A mut 9.63
T* T* WT 7.41
T* A het 49.63
C T* het 33.33
Total non-parental 17.04
c.301 c.430 (n ¼ 102)
ALG12-CDG (ALG12: c.[301G>A];[430G>A]), dbSNP: rs121907933, rs121907932 A A mut 2.94
G* G* WT 9.8
G* A het 50
A G* het 37.25
Total non-parental 12.74
c.509 c.584 (n ¼ 115)
DPAGT1-CDG (DPAGT1: c.[509A>G];[584C>G]), dbSNP: rs28934876; ClinVar: SCV000256096 G G mut 2.61
A* C* WT 0.87
A* G het 54.78
G C* het 41.74
Total non-parental 3.51
c.1037 c.1187þ1 (n ¼ 103)
ALG1-CDG (ALG1: c.[1037C>G];[1187þ1G>A]), dbSNP: rs398124348, rs374928784 G A mut 4.85
C* G* WT 86.41
C* A het 2.91
G G* het 5.83
Total non-parental 91.26
Single-allele cloning and sequencing reveals non-parental genotypes in genomic DNA from cultured fibroblasts of multiple CDG-affected individuals. Allele ge-
notypes are shown in the first two columns; the reference alleles are indicated by an asterisk. Each row represents a single allele and the frequency of this allele. SNV
accession numbers are provided in respective order for each variant.(ALG12-CDG [OMIM: 607143]), DPAGT1 (DPAGT1-CDG
[OMIM: 608093]), and ALG1 (ALG1-CDG [OMIM:
608540]) (Table 2). Characterization of >100 clones342 The American Journal of Human Genetics 98, 339–346, Februaryfrom each cell line detected alleles with non-parental ge-
notypes (Table 2); Sanger sequencing results from repre-
sentative clones are shown with chromatograms in4, 2016
Figure 2. Recombination Frequency Increases with Distance
Recombination frequency (percentage) in fibroblasts is plotted
versus distance (nucleotides, nt). CDG samples are marked with
an open circle and the control sample with a plus sign. The solid
line represents a linear model for the recombination versus dis-
tance for the CDGs (y ¼ 0.1137*x-3.1628, R2 ¼ 0.9743). Dashed
lines represent the 95% confidence interval and dotted lines the
95% prediction interval.Figure S1 and FASTA sequences in Table S2. The frequency
of non-parental genotypes ranged from approximately
1.5% to 90%, with a strong correlation between the fre-
quency of recombinant genotypes and the chromosomal
distance between the variants (R2 ¼ 0.97, Figure 2). In
contrast, using Pacific Biosciences (PacBio) amplicon
sequencing, recombination analysis of compound hetero-
zygous SNVs at the GEN1 (OMIM: 612449) locus in
cultured fibroblasts from an unaffected individual showed
only 27% recombination across 800 nucleotides (Table 3;
NIH Intramural Sequencing Center, primer sequences in
Table S1).23 This recombination frequency is well outside
of the 95% prediction interval calculated from the CDG
linear model (Figure 2).
Digital PCR analysis of SNV frequency in the other CDG
cell lines also detected evidence for both reciprocal and
nonreciprocal mitotic recombination processes. We did
not observe a decrease in SNV frequency among the
PMM2-, ALG3-, ALG12-, or DPAGT1-CDG cell lines (Ta-
ble 2 and Figures 3B–3G), whereas we did observe a loss
of both pathogenic SNVs for the ALG1-CDG cell line
(Figure 3G) and loss of one reference SNV (MPI c.1205A)
for the MPI-CDG cell line (Figure 3C). The loss of both
pathogenic variants in the ALG1-CDG cell line suggests
either nonreciprocal mitotic recombination generating
two wild-type alleles or reciprocal mitotic recombination
generating a wild-type allele and subsequent loss of hetero-
zygosity. In total, these results provide evidence thatThe Americincreased rates of mitotic intragenic recombination, recip-
rocal and nonreciprocal, occur in CDG tissues and are a
potential mechanism for survival and variability in indi-
viduals with CDGs.
The above observations suggest either that the muta-
tions and genes involved in these CDGs reside at recombi-
nation hotspots or that there is selection of cells with
increased levels of functional enzyme. The distribution of
the studied genes around the genome and the absence of
known recombination hotspots at those locations sug-
gested to us that the studied CDG genes do not reside at
recombination hotspots. Additionally, because the recom-
bination frequency across these genes and samples had a
linear correlation with distance between the heterozygous
mutations, we concluded that it was more likely that the
recombination rate across each of these genes was compa-
rable rather than that each pair of mutations resided
within intragenic recombination hotspots with compara-
ble recombination rates.24
These findings also suggest that, as has been observed
for Bloom syndrome (OMIM: 210900) and WRN helicase
(OMIM: 604611)-deficient cells,25,26 recombination and
the consequent mosaicism contribute to the variable ex-
pressivity of CDGs along with the nature of the muta-
tion.9,11,25–27 Similarly, there are several reports of somatic
and revertant mosaicism in human disease, including ich-
thyosis with confetti (OMIM: 6091650),28 tyrosinemia
type I (OMIM: 276700), severe combined immunodefi-
ciency (autosomal [OMIM: 102700] and X-linked
[OMIM: 300400]), Wiskott-Aldrich syndrome (OMIM:
301000), epidermolysis bullosa (OMIM: 148066), and
Fanconi anemia (OMIM: 607139 and 227645) (reviewed
by Hirschorn).29 Among these disorders, there is evidence
of gene conversion and somatic recombination as under-
lying mechanisms for reversion, indicating that our obser-
vations in the CDGs are not isolated but reflect an impor-
tant, albeit rare, phenomenon in human physiology.
Mitotic recombination has also been reported both in vivo
and in vitro in a mouse model heterozygous for an Aprt
mutant allele, further supporting a model whereby selec-
tive pressure from disease can lead to increased abun-
dance of recombinant products in the absence of DNA
replication defects.30 If an in vivo recombination event
occurs more frequently or earlier in life, there is an oppor-
tunity for cells expressing wild-type protein to outcom-
pete cells expressing mutant protein and ameliorate the
phenotype, as has been observed in Kindler syndrome
(OMIM: 173650), a human skin fragility disorder,31 and
giving the appearance of an increased mitotic recombina-
tion rate.
Here we have provided evidence of mitotic intragenic
recombination in compound heterozygous CDGs.
This suggests that recombination between compound
heterozygous alleles of glycosylation genes causes rever-
sion to a wild-type allele and that survival or growth
advantage of cells with the wild-type allele ameliorates
the phenotype of the CDGs. A model of CDG survivalan Journal of Human Genetics 98, 339–346, February 4, 2016 343
Figure 3. Digital PCR Quantification of
SNV Frequencies in Cultured Fibroblasts
of CDG-Affected Individuals
The frequency of the reference SNV is
shown for unaffected control cells (‘‘WT’’)
versus primary fibroblast lines from indi-
viduals with CDG-causing mutations
(‘‘CDG’’) in PMM2 (A), MPI (B), ALG3 (C),
ALG12 (D), DPAGT1 (E), and ALG1 (F).
Error bars indicate SD.attributed to mitotic intragenic recombination within
somatic cells is further supported by residual enzymatic
activity in CDG individual cells8,9 and the small number
of reported homozygous mutations among the
CDGs.12,13Accession Numbers
The accession numbers for the previously unreported CDG vari-
ants studied in this paper are ClinVar: SCV000256094 (MPI;
c.1205A>G), SCV000256095 (MPI; c.1253G>A), SCV000256096
(DPAGT1; c.584C>G), and SCV000256097 (c.329G>A).Supplemental Data
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Table 3. Single-Allele Sequencing Results of an Unaffected Individual
Sample (Variants), Accession Genotype Category Percentage
c.1638 c.2445 (n ¼ 1,269)
Control blood (GEN1: c.[1638T>A];[2445C>T]), dbSNP: rs61762986, rs148781334 A T mut 11.98
T* C* WT 13.95
T* T het 36.17
A T* het 37.90
Total non-parental 25.93
c.1638 c.2445 (n ¼ 1,115)
Control fibroblasts (GEN1: c.[1638T>A];[2445C>T]), dbSNP: rs61762986, rs148781334 A T mut 15.52
T* C* WT 12.11
T* T het 33.72
A T* het 38.65
Total non-parental 27.62
Sequence analysis via PacBio amplicon sequencing of single alleles in a healthy individual detects a low level of mitotic recombination in blood and fibroblasts.
Allele genotypes are shown in the first two columns; the reference alleles are indicated by an asterisk. Each row represents a single allele and the frequency of this
allele in the sequenced population. SNV accession numbers are provided in respective order for each variant.References
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